GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)

INR 2303.2

(-1.26%)

Long Term Debt Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual long term debt in 2023 was 64.69 Million INR , up 86.97% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly long term debt in 2024 Q2 was - INR , down 0.0% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported annual long term debt of 34.6 Million INR in 2022, down -54.61% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported annual long term debt of 76.23 Million INR in 2021, down -62.35% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported quarterly long term debt of - INR for 2024 Q2, down 0.0% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported quarterly long term debt of 74.2 Million INR for 2023 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Long Term Debt of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Long Term Debt	Long Term Debt Growth
2023	64.69 Million INR	86.97%
2022	34.6 Million INR	-54.61%
2021	76.23 Million INR	-62.35%
2020	202.49 Million INR	-24.61%
2019	268.61 Million INR	15075.82%
2018	1.77 Million INR	-69.64%
2017	5.83 Million INR	-41.05%
2016	9.89 Million INR	-37.99%
2015	15.95 Million INR	-39.26%
2014	26.26 Million INR	-27.16%
2013	36.05 Million INR	-12.97%
2012	41.42 Million INR	-15.55%
2011	49.05 Million INR	-4.97%
2010	51.61 Million INR	-4.74%
2009	54.18 Million INR	0.0%
2008	- INR	-100.0%
2007	57.97 Million INR	4.71%
2006	55.37 Million INR	14.07%
2005	48.54 Million INR	26.25%
2004	38.44 Million INR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	- INR	0.0%
2024 Q2	- INR	0.0%
2023 Q2	74.2 Million INR	0.0%
2023 Q4	64.69 Million INR	0.0%
2023 FY	64.69 Million INR	86.97%
2023 Q3	- INR	-100.0%
2023 Q1	- INR	-100.0%
2022 Q2	88.6 Million INR	0.0%
2022 FY	34.6 Million INR	-54.61%
2022 Q4	34.6 Million INR	0.0%
2022 Q3	- INR	-100.0%
2022 Q1	- INR	-100.0%
2021 Q1	- INR	-100.0%
2021 Q4	76.23 Million INR	0.0%
2021 Q2	128 Million INR	0.0%
2021 FY	76.23 Million INR	-62.35%
2021 Q3	- INR	-100.0%
2020 Q4	202.49 Million INR	0.0%
2020 FY	202.49 Million INR	-24.61%
2020 Q2	279.2 Million INR	0.0%
2020 Q3	- INR	-100.0%
2020 Q1	- INR	-100.0%
2019 Q4	268.61 Million INR	0.0%
2019 FY	268.61 Million INR	15075.82%
2019 Q3	- INR	-100.0%
2019 Q2	431 Million INR	0.0%
2019 Q1	- INR	-100.0%
2018 Q4	1.77 Million INR	0.0%
2018 FY	1.77 Million INR	-69.64%
2018 Q1	- INR	0.0%
2017 FY	5.83 Million INR	-41.05%
2016 FY	9.89 Million INR	-37.99%
2015 FY	15.95 Million INR	-39.26%
2014 FY	26.26 Million INR	-27.16%
2013 FY	36.05 Million INR	-12.97%
2012 FY	41.42 Million INR	-15.55%
2011 FY	49.05 Million INR	-4.97%
2010 FY	51.61 Million INR	-4.74%
2009 FY	54.18 Million INR	0.0%
2008 FY	- INR	-100.0%
2007 FY	57.97 Million INR	4.71%
2006 FY	55.37 Million INR	14.07%
2005 FY	48.54 Million INR	26.25%
2004 FY	38.44 Million INR	0.0%

Peer Long Term Debt Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Long Term Debt	Long Term Debt Difference
Abbott India Limited	367.6 Million INR	82.402%
Cipla Limited	2.25 Billion INR	97.13%
Gland Pharma Limited	1.06 Billion INR	93.928%
Kopran Limited	166.02 Million INR	61.036%
Marksans Pharma Limited	1.9 Billion INR	96.596%
NGL Fine-Chem Limited	7.44 Million INR	-768.569%
Pfizer Limited	543.5 Million INR	88.097%
Sanofi India Limited	139 Million INR	53.46%
SMS Pharmaceuticals Limited	1.22 Billion INR	94.701%
TTK Healthcare Limited	7.98 Million INR	-709.954%